Ann: Positive Xanamem biomarker trial published in Jnl Alz Dis, page-87

XanaHES did not meet its efficacy endpoints. What ACW did later in 2021/22 was use the blood samples from that failed study and selected only those with a high pTau biomarker. It then looked at the XanaHES results for that selected set of samples to establish if there was something meaningful from the use of Xanamem. There were various endpoint tests that were evaluated for significance. One endpoint showed statistical significance but most of the rest were statistically insignificant. Because of this selectivity only patients with high pTau will be selected. However, it will have to be a much higher sample size in order to have sufficient statistical power. So in essence the blood sampling of XanaHES does not meet the necessary requirements for a proper efficacy test IMO. Having said that the industry certainly understands and can put some faith in using biomarkers for patient selection. So the re examination of the XanaHES data results in this light makes good sense and hopefully will result in a positive interim analysis result for the XanaAD trial. DYOR